Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Why treat early multiple sclerosis patients?

G Comi

    Current Opinion in Neurology
    |June 28, 2000
    PubMed
    Summary

    Early immunomodulatory treatment for multiple sclerosis (MS) modestly reduces disease activity and disability. Evidence suggests early intervention is crucial, as inflammation causes irreversible axonal damage even in early MS stages.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

    Journal of neurology, neurosurgery, and psychiatry·2011
    Same author

    Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue.

    AJNR. American journal of neuroradiology·2011
    Same author

    Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years.

    AJNR. American journal of neuroradiology·2011
    Same author

    Cortical lesions in children with multiple sclerosis.

    Neurology·2011
    Same author

    Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis.

    Cerebral cortex (New York, N.Y. : 1991)·2011
    Same author

    A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

    European journal of neurology·2011

    Area of Science:

    • Neurology
    • Immunology
    • Neuroscience

    Background:

    • Class 1 clinical trials show immunomodulatory treatments like interferon beta and glatiramer acetate reduce disease activity and disability in relapsing remitting multiple sclerosis.
    • Interferon beta-1b demonstrates positive effects in secondary progressive multiple sclerosis.
    • While clinical effects are modest, magnetic resonance imaging reveals significant reduction in inflammatory activity.

    Discussion:

    • New pathological studies and advanced MRI techniques indicate early inflammatory activity causes irreversible axonal damage in multiple sclerosis.
    • The degree of inflammation at clinical presentation can predict long-term disability.
    • These findings underscore the importance of early therapeutic intervention.

    Key Insights:

    • Immunomodulatory therapies offer benefits for multiple sclerosis patients.
    • Early diagnosis and treatment are critical for mitigating long-term disability.
    • Inflammation is a key driver of irreversible neurological damage in MS.

    Outlook:

    • Further research into early intervention strategies for multiple sclerosis is warranted.
    • The Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study supports the benefits of early treatment.
    • Optimizing treatment timing may improve long-term outcomes for individuals with multiple sclerosis.

    Related Experiment Videos